Kyverna Therapeutics shares are trading lower. The company earlier released a presentation on KYV-101, its CD19 CAR T-cell candidate
Portfolio Pulse from Benzinga Newsdesk
Kyverna Therapeutics shares are trading lower following the release of a presentation on KYV-101, its CD19 CAR T-cell candidate.
June 14, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kyverna Therapeutics shares are trading lower after the company released a presentation on KYV-101, its CD19 CAR T-cell candidate.
The release of the presentation on KYV-101 has led to a negative market reaction, causing Kyverna Therapeutics shares to trade lower. This suggests that investors may have concerns about the candidate or the information presented.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100